A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Steven A. Limentani, Mario Csampone, Thierry Dorval, Giuseppe Curigliano, Richard de Boer, Charles Vogel, Shane White, Thomas Bachelot, Jean Luc Canon, Mary Disis, Ahmad Awada, Martine Berlière, Frédéric Amant, Ellis Levine, Wivine Burny, Andrea Callegaro, Pedro Miguel De Sousa Alves, Jamila Louahed, Vincent Brichard, Frédéric F. Lehmann

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences